Publications

Journal Article
Review
Ppublish 532 citations
Open access — free full text available
Open access
Electronic publication date
July 1, 2020

View on Pubmed.gov 32360420 | View on doi.org 10.1016/j.cytog... | View the free full text Full text

Cytokine storm intervention in the early stages of COVID-19 pneumonia.

Search for publications in this journal Cytokine Growth Factor Rev

  • Xinjuan Sun

    Search for this expert
    1
  • Tianyuan Wang

    Search for this expert
    1
  • Dayong Cai

    Search for this expert
    2
  • Zhiwei Hu 1
  • Jin'an Chen

    Search for this expert
    1
  • Hui Liao

    Search for this expert
    3
  • Liming Zhi

    Search for this expert
    4
  • Hongxia Wei

    Search for this expert
    5
  • Zhihong Zhang

    Search for this expert
    6
  • Yuying Qiu

    Search for this expert
    7
  • Jing Wang

    Search for this expert
    Contact the corresponding author.
    Reported by OpenAlex: verify on the publication before relying on it.
    8
  • Aiping Wang
    Contact the corresponding author.
    Reported by OpenAlex: verify on the publication before relying on it.
    9

Abstract

Clinical intervention in patients with corona virus disease 2019 (COVID-19) has demonstrated a strong upregulation of cytokine production in patients who are critically ill with SARS-CoV2-induced pneumonia. In a retrospective study of 41 patients with COVID-19, most patients with SARS-CoV-2 infection developed mild symptoms, whereas some patients later developed aggravated disease symptoms, and eventually passed away because of multiple organ dysfunction syndrome (MODS), as a consequence of a severe cytokine storm. Guidelines for the diagnosis and treatment of SARS-CoV-2 infected pneumonia were first published January 30, 2020; these guidelines recommended for the first time that cytokine monitoring should be applied in severely ill patients to reduce pneumonia related mortality. The cytokine storm observed in COVID-19 illness is also an important component of mortality in other viral diseases, including SARS, MERS and influenza. In view of the severe morbidity and mortality of COVID-19 pneumonia, we review the current understanding of treatment of human coronavirus infections from the perspective of a dysregulated cytokine and immune response.

References

Respirology. 2006 Nov;11(6):715-22

J Immunother Cancer. 2018 Jun 15;6(1):56

Cell. 2011 Sep 16;146(6):980-91

Immunotherapy. 2016 Jul;8(8):959-70

Cited by 532 citations (total)

Journal Article

Comprehensive transcriptomic analysis of COVID-19 blood, lung, and airway.

Electronic publication date April 15, 2021

Search for publications in this journal Sci Rep

Andrea R Daamen [...] Peter E Lipsky et al.

SARS-CoV2 is a previously uncharacterized coronavirus and causative agent of the COVID-19 pandemic. The host response to SARS-CoV2 has not...

Journal Article Research Support, Non-U.S. Gov't

Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients.

Electronic publication date June 25, 2021

Search for publications in this journal Front Immunol

Zhenyan Wang [...] Hongzhou Lu et al.

Dysregulation of immune response was observed in COVID-19 patients. Thymosin alpha 1 (Tα1) is used in the management of COVID-19,...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances

Copyright

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.